

Ref: FOI/GS/ID 9166

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

24 June 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Oncology Breast Cancer.

You asked: All questions are shown as received by the Trust.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- a. Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- b. Abemaciclib + Fulvestrant*
- c. Alpelisib + Fulvestrant*
- d. Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide*
- e. Aromatase Inhibitor as a single agent*
- f. Atezolizumab*
- g. Capecitabine as a single agent*
- h. Carboplatin + Paclitaxel*
- i. Eribulin as a single agent or in combination*
- j. Everolimus + Exemestane*
- k. Fulvestrant as a single agent*
- l. Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- m. Palbociclib + Fulvestrant*
- n. Parp Inhibitors (Olaparib/Talazoparib)*
- o. Pembrolizumab*
- p. Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- q. Ribociclib + Fulvestrant*
- r. Sacituzumab Govitecan*
- s. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- t. Trastuzumab deruxtecan*
- u. Trastuzumab as a single agent or in combination*
- v. Trastuzumab emtansine*
- w. Any other active systemic anti-cancer therapy*

Q2. *If breast cancer is not treated at or within the Trust, where are patients referred?*

Trust response:

1.

a	50
b	0
c	0
d	37
e	1
f	6
g	21
h	7
i	1
j	5
k	1
l	56
m	23
n	1
o	6
p	23
q	5
r	1
s	16
t	2
u	86
v	9
w	17

2. Patients can be referred to Queen Victoria Hospital, East Grinstead if they require a certain type of reconstruction.